Skip to main content

Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance

Edited by:
Cristophe Nicot, PhD, Kansas University Medical Center, United States of America

Submission Status: Closed

This Collection is no longer accepting submissions.


Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.' 

This Collection welcomes submission of Reviews and Correspondence Articles only. 

About the collection

Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.' 

This Collection aims to showcase cutting-edge research in identification, validation, and clinical application of biomarkers that hold promise for accurate cancer diagnosis, prognosis, and prediction of drug resistance. We welcome Correspondences that address this multifaceted role of biomarkers in guiding personalized treatment strategies, improving patient outcomes, and advancing our understanding of cancer biology. Please note that this Collection will not accept any study based on TCGA analyses without independent cohort validation.

Each Correspondence should start with “To the Editor”, include a maximum of 2 tables or figures, a maximum of 15 references and up to 1500 words in text. It should also have two subsections to better delineate the content, Abstract and Results/Discussion. 

This Collection welcomes submission of Correspondence Articles only. 

Image credit: © [M] freshidea / stock.adobe.com

  1. The lysine-specific demethylase 5 (KDM5) family, a key post-translational modification of chromatin, can shape tumor immune microenvironment. Here, we performed an extensive clinical and bioinformatic analysis...

    Authors: Xiaofeng Li, Zhishan Zhang, Yingying Li, Lijin Chen, Yan Huang, Lijuan Su, Wenjun Xu, Yanni Hong, Jianjiao Li, Mujin Chen, Hongkui Yang, Hong Zhao and Bin Zhao
    Citation: Molecular Cancer 2024 23:281
  2. In the realm of cancer research, the tumor microenvironment (TME) plays a crucial role in tumor initiation and progression, shaped by complex interactions between cancer cells and surrounding non-cancerous cel...

    Authors: Hua Wang, Tao Wang, Shuxiang Yan, Jinxin Tang, Yibo Zhang, Liming Wang, Haodong Xu and Chao Tu
    Citation: Molecular Cancer 2024 23:268
  3. Millions of new cases of cancer are diagnosed worldwide each year, making it a serious public health concern. Developments in customized therapy and early detection have significantly enhanced treatment for an...

    Authors: Nan Zhang, Hao Zhang, Shuyu Li, Wantao Wu, Peng Luo, Zaoqu Liu, Yu Chen, Zhiwei Xia, Chenshen Huang and Quan Cheng
    Citation: Molecular Cancer 2024 23:258
  4. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for non-small cell lung cancer (NSCLC). The variability in patient responses necessitates a blood-based, multi-cohort gene signat...

    Authors: Shaoqiu Chen, Fangfang Liu, Yuanyuan Fu, Chris K. Deng, Jeffrey A. Borgia, Abdul-Ghani Ayman, Masaki Nasu, Mayumi Jijiwa, Hua Yang, Ting Gong, Junlong Wang, Zhougui Ling, Xiaoyan Wang, Hongwei Wang, Qian Chu and Youping Deng
    Citation: Molecular Cancer 2024 23:247
  5. Cancer is the leading cause of disease-related mortality in children. Causes of leukemia, the most common form, are largely unknown. Growing evidence points to an origin in-utero, when global redistribution of DN...

    Authors: Akram Ghantous, Semira Gonseth Nusslé, Farah J. Nassar, Natalia Spitz, Alexei Novoloaca, Olga Krali, Eric Nickels, Vincent Cahais, Cyrille Cuenin, Ritu Roy, Shaobo Li, Maxime Caron, Dilys Lam, Peter Daniel Fransquet, John Casement, Gordon Strathdee…
    Citation: Molecular Cancer 2024 23:238
  6. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, providing significant benefit to patients across various tumour types, including melanoma. However, around 40% of melanoma patients do not...

    Authors: Su Yin Lim, Ines Pires da Silva, Nurudeen A. Adegoke, Serigne N. Lo, Alexander M. Menzies, Matteo S. Carlino, Richard A. Scolyer, Georgina V. Long, Jenny H. Lee and Helen Rizos
    Citation: Molecular Cancer 2024 23:228
  7. Recent advances in cancer research have highlighted the pivotal role of tertiary lymphoid structures (TLSs) in modulating immune responses, particularly in breast cancer (BRCA). Here, we performed an integrate...

    Authors: Shuyu Li, Nan Zhang, Hao Zhang, Zhifang Yang, Quan Cheng, Kang Wei, Meng Zhou and Chenshen Huang
    Citation: Molecular Cancer 2024 23:216
  8. Metastasis has been one of the primary reasons for the high mortality rates associated with tumours in recent years, rendering the treatment of current malignancies challenging and representing a significant c...

    Authors: Jiachi Jia, Yuhang Wang, Mengjia Li, Fuqi Wang, Yingnan Peng, Junhong Hu, Zhen Li, Zhilei Bian and Shuaixi Yang
    Citation: Molecular Cancer 2024 23:200
  9. Anti-angiogenic agents elicit considerable immune modulatory effects within the tumor microenvironment, underscoring the rationale for synergistic clinical development of VEGF and immune checkpoint inhibitors ...

    Authors: Sophie Cousin, Jean-Philippe Guégan, Kohei Shitara, Lola Jade Palmieri, Jean Philippe Metges, Simon Pernot, Shota Fukuoka, Shohei Koyama, Hiroyoshi Nishikawa, Carine A. Bellera, Antoine Adenis, Carlos A. Gomez-Roca, Philippe Alexandre Cassier, Antoine Hollebecque, Coralie Cantarel, Michèle Kind…
    Citation: Molecular Cancer 2024 23:197
  10. CD8+ T cells are the workhorses executing adaptive anti-tumour response, and targets of various cancer immunotherapies. Latest advances have unearthed the sheer heterogeneity of CD8+ tumour infiltrating lymphocyt...

    Authors: Yikan Sun, Eloy Yinwang, Shengdong Wang, Zenan Wang, Fangqian Wang, Yucheng Xue, Wenkan Zhang, Shenzhi Zhao, Haochen Mou, Shixin Chen, Lingxiao Jin, Binghao Li and Zhaoming Ye
    Citation: Molecular Cancer 2024 23:193
  11. Cancer-associated fibroblasts (CAFs) are a diverse stromal cell population within the tumour microenvironment, where they play fundamental roles in cancer progression and patient prognosis. Multiple lines of e...

    Authors: Zhengjun Lin, Guoqing Li, Ke Jiang, Zhihong Li and Tang Liu
    Citation: Molecular Cancer 2024 23:191
  12. Liver cancer is a global health challenge, causing a significant social-economic burden. Hepatocellular carcinoma (HCC) is the predominant type of primary liver cancer, which is highly heterogeneous in terms o...

    Authors: Yau-Tuen Chan, Cheng Zhang, Junyu Wu, Pengde Lu, Lin Xu, Hongchao Yuan, Yibin Feng, Zhe-Sheng Chen and Ning Wang
    Citation: Molecular Cancer 2024 23:189
  13. The drug efflux transporter P-glycoprotein, encoded by the ABCB1 gene, promotes acquired chemoresistance. We explored the presence and clinical relevance of circulating cell-free ABCB1 transcripts (cfABCB1tx) in ...

    Authors: Franziska Maria Schwarz, Jan Dominik Kuhlmann, Jorrin Kämpfer, Anna Klimova, Daniel Martin Klotz, Lisa Freitag, Pia Herrmann, Viktoria Zinnow, Janice Smith, Theresia Scheller, Wolfgang Walther, Pauline Wimberger and Ulrike Stein
    Citation: Molecular Cancer 2024 23:174
  14. Early detection of colorectal cancer (CRC) significantly enhances patient outcomes. Conventional CRC screening tools, like endoscopy and stool-based tests, have constraints due to their invasiveness or subopti...

    Authors: Yibo Gao, Dandan Cao, Mengfan Li, Fuqiang Zhao, Pei Wang, Shiwen Mei, Qianqian Song, Pei Wang, Yanli Nie, Wei Zhao, Sizhen Wang, Hai Yan, Xishan Wang, Yuchen Jiao and Qian Liu
    Citation: Molecular Cancer 2024 23:173
  15. Circular RNAs (circRNAs) are unique noncoding RNAs that have a closed and stable loop structure generated through backsplicing. Due to their conservation, stability and tissue specificity, circRNAs can potenti...

    Authors: Wenjie Zhang, Chen Xu, Zhipeng Yang, Jingshi Zhou, Wei Peng, Xuan Zhang, Haimin Li, Shibin Qu and Kaishan Tao
    Citation: Molecular Cancer 2024 23:171
  16. In the KEYNOTE-811 study, anti-HER2 and immunotherapy treatments resulted in longer survival in HER2-positive gastric cancer patients with CPS ≥ 1, whereas CPS < 1 patients lacked notable benefits. We studied ...

    Authors: Yang Chen, Keren Jia, Xiaoyi Chong, Yi Xie, Lei Jiang, Haoxin Peng, Dan Liu, Jiajia Yuan, Yanyan Li, Xujiao Feng, Yu Sun, Jian Li, Xiaotian Zhang and Lin Shen
    Citation: Molecular Cancer 2024 23:169
  17. PARP inhibitor (PARPi) therapy has transformed outcomes for patients with homologous recombination DNA repair (HRR) deficient ovarian cancers, for example those with BRCA1 or BRCA2 gene defects. Unfortunately, PA...

    Authors: Ksenija Nesic, John J. Krais, Yifan Wang, Cassandra J. Vandenberg, Pooja Patel, Kathy Q. Cai, Tanya Kwan, Elizabeth Lieschke, Gwo-Yaw Ho, Holly E. Barker, Justin Bedo, Silvia Casadei, Andrew Farrell, Marc Radke, Kristy Shield-Artin, Jocelyn S. Penington…
    Citation: Molecular Cancer 2024 23:158
  18. Chemotherapy in combination with immunotherapy has gradually shown substantial promise to increase T cell infiltration and antitumor efficacy. However, paclitaxel in combination with immune checkpoint inhibito...

    Authors: Hong-Xiang Shi, Hang-Tian Tao, Jin-Jin He, Feng-Yi Zhu, Cui-Qing Xie, Yu-Na Cheng, Li-Li Hou, Hua Sun, Chang-Jiang Qin, Dong Fang and Song-Qiang Xie
    Citation: Molecular Cancer 2024 23:152
  19. Metastatic colorectal cancer (mCRC) presents significant challenges in clinical management due to its heterogeneity and variable response to treatment. In this study, we conducted comprehensive small RNA (sRNA...

    Authors: Robin Mjelle, Are K. Kristensen, Tora S. Solheim, Ganna S. Westvik, Hege Elvebakken and Eva Hofsli
    Citation: Molecular Cancer 2024 23:133
  20. TFE3-rearranged renal cell carcinoma (TFE3-rRCC) is a rare but highly heterogeneous renal cell carcinoma (RCC) entity, of which the clinical treatment landscape is largely undefined. This study aims to evaluate a...

    Authors: Junjie Zhao, Yanfeng Tang, Xu Hu, Xiaoxue Yin, Yuntian Chen, Junru Chen, Haoyang Liu, Haolin Liu, Jiayu Liang, Xingming Zhang, Jinge Zhao, Sha Zhu, Yuchao Ni, Zhipeng Wang, Jindong Dai, Zilin Wang…
    Citation: Molecular Cancer 2024 23:132
  21. The clinical heterogeneity of early-stage endometrial cancer (EC) is worthy of further study to identify high-quality prognostic markers and their potential role in aggressive tumor behavior. Mutation of TP53 ...

    Authors: Xiaodan Mao, Xiaoyue Tang, Jingxuan Ye, Shuxia Xu, Yue Wang, Xianhua Liu, Qibin Wu, Xite Lin, Maotong Zhang, Jiangfeng Liu, Juntao Yang and Pengming Sun
    Citation: Molecular Cancer 2024 23:127
  22. Breast cancer (BC) is the most frequent malignant cancer diagnosis and is a primary factor for cancer deaths in women. The clinical subtypes of BC include estrogen receptor (ER) positive, progesterone receptor...

    Authors: Chang-Yun Li, Wanhe Wang, Chung-Hang Leung, Guan-Jun Yang and Jiong Chen
    Citation: Molecular Cancer 2024 23:109
  23. Accurate presurgical prediction of pathological complete response (pCR) can guide treatment decisions, potentially avoiding unnecessary surgeries and improving the quality of life for cancer patients. We devel...

    Authors: Pinli Yue, Fenglong Bie, Jiarun Zhu, Lin-Rui Gao, Zhendiao Zhou, Guangyu Bai, Xiaobing Wang, Ziyi Zhao, Ze-Fen Xiao, Yong Li, Aiping Zhou, Wen-Yang Liu, Yuchen Jiao and Shugeng Gao
    Citation: Molecular Cancer 2024 23:96
  24. The Neurotrophic tyrosine receptor kinase (NTRK) family plays important roles in tumor progression and is involved in tumor immunogenicity. Here, we conducted a comprehensive bioinformatic and clinical analysis t...

    Authors: Congren Wang, Yingying Li, Jinyuan Huang, Huimeng Yan and Bin Zhao
    Citation: Molecular Cancer 2024 23:81
  25. For decades, great strides have been made in the field of immunometabolism. A plethora of evidence ranging from basic mechanisms to clinical transformation has gradually embarked on immunometabolism to the cen...

    Authors: Qin Dang, Borui Li, Bing Jin, Zeng Ye, Xin Lou, Ting Wang, Yan Wang, Xuan Pan, Qiangsheng Hu, Zheng Li, Shunrong Ji, Chenjie Zhou, Xianjun Yu, Yi Qin and Xiaowu Xu
    Citation: Molecular Cancer 2024 23:72
  26. Ovarian cancer is the leading cause of gynecological cancer-related death. Drug resistance is the bottleneck in ovarian cancer treatment. The increasing use of novel drugs in clinical practice poses challenges...

    Authors: Ling Wang, Xin Wang, Xueping Zhu, Lin Zhong, Qingxiu Jiang, Ya Wang, Qin Tang, Qiaoling Li, Cong Zhang, Haixia Wang and Dongling Zou
    Citation: Molecular Cancer 2024 23:66
  27. Urine-based testing is promising for noninvasive diagnosis of urothelial carcinoma (UC) but has suboptimal sensitivity for early-stage tumors. Herein, we developed a multitarget urine tumor DNA test, UI-Seek, ...

    Authors: Junlong Wu, Yuda Lin, Kaiwei Yang, Xiao Liu, Huina Wang, Tingting Yu, Ran Tao, Jing Guo, Libin Chen, Huanqing Cheng, Feng Lou, Shanbo Cao, Wei Yu, Hailong Hu and Dingwei Ye
    Citation: Molecular Cancer 2024 23:57
  28. the problem in early diagnosis of sporadic cancer is understanding the individual’s risk to develop disease. In response to this need, global scientific research is focusing on developing predictive models bas...

    Authors: Natalia Malara, Maria Laura Coluccio, Fabiana Grillo, Teresa Ferrazzo, Nastassia C. Garo, Giuseppe Donato, Annamaria Lavecchia, Franco Fulciniti, Anna Sapino, Eliano Cascardi, Antonella Pellegrini, Prassede Foxi, Cesare Furlanello, Giovanni Negri, Guido Fadda, Arrigo Capitanio…
    Citation: Molecular Cancer 2024 23:32
  29. Heat shock proteins play crucial roles in various biochemical processes, encompassing protein folding and translocation. HSP90B1, a conserved member of the heat shock protein family, growing evidences have dem...

    Authors: Xiaoliang Huang, Weiming Zhang, Na Yang, Yujie Zhang, Tianyu Qin, Hanyi Ruan, Yan Zhang, Chao Tian, Xianwei Mo, Weizhong Tang, Jungang Liu and Beibei Zhang
    Citation: Molecular Cancer 2024 23:19
  30. Triple negative breast cancer (TNBC) is a heterogeneous group of tumors which lack estrogen receptor, progesterone receptor, and HER2 expression. Targeted therapies have limited success in treating TNBC, thus ...

    Authors: Heba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, Denen Shian, Deema Zaid, Ariel M. Rubinstein, Amir Sonnenblick, Tamar Peretz-Yablonsky, Avital Granit, Einat Carmon, Ishwar N. Kohale, Judy C. Boughey, Matthew P. Goetz, Liewei Wang, Forest M. White and Nataly Kravchenko-Balasha
    Citation: Molecular Cancer 2024 23:17
  31. The tumor microenvironment (TME) is an intricate system comprised of tumor cells and the surrounding cellular and non-cellular components, exerting a pivotal influence on the initiation and progression of tumo...

    Authors: Xinming Su, Chenhao Liang, Ruixiu Chen and Shiwei Duan
    Citation: Molecular Cancer 2024 23:13

    The Correction to this article has been published in Molecular Cancer 2025 24:87

Submission Guidelines

Back to top

This Collection welcomes submission of Correspondence Articles only. 

Please read our submission guidelines before submitting your article. Articles for this Collection should be submitted via our submission system. During the submission process you will be asked whether you are submitting to a Collection, please select "Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.